Lifileucel Demonstrates Efficacy in Advanced Mucosal Melanoma Following Progression on Immune Checkpoint Inhibitors
Source: OncLive, October 2023
Lifileucel demonstrated clinically meaningful activity in patients with advanced mucosal melanoma who experienced disease progression on immune checkpoint inhibitors, according to findings from a subgroup of patients in the phase 2 C-144-01 study.
Lifileucel demonstrated clinically meaningful activity in patients with advanced mucosal melanoma who experienced disease progression on immune checkpoint inhibitors, according to findings from a subgroup of patients in the phase 2 C-144-01 study (NCT02360579) presented during the 2023 ESMO Congress.
At a median follow-up of 35.7 months, patients who received the tumor-infiltrating lymphocyte therapy (n = 12) experienced an objective response rate (ORR) of 50% (95% CI, 21.1%-78.9%), including 1 patient who achieved a complete response. Four patients had stable disease and 2 had disease progression (PD). Notably, at the July 15, 2022, data cutoff, 4 of the 6 responders had durable and ongoing responses.